VEGF-receptor signal transduction

Trends in Biochemical Sciences

Volumn 28, Issue 9, 2003, Pages 488-494

  Cross, Michael J ^a   Dixelius, Johan ^a   Matsumoto, Taro ^b   Claesson Welsh, Lena ^a  

^a Department of Genetics and Pathology ^*  (Sweden)

^b NIHON UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; LIGAND;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; HEMATOPOIESIS; HUMAN; LYMPH NODE; LYMPHANGIOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; VASCULARIZATION; ANIMAL; ENZYME SPECIFICITY; GENETICS; HEMATOPOIETIC STEM CELL; LYMPH NODE METASTASIS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; HEMATOPOIETIC STEM CELLS; HUMANS; LIGANDS; LYMPHATIC METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 0642306485     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0004(03)00193-2     Document Type: Review

References (80)

1. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer. 2:2002;38-47.
2. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29:(6 Suppl. 16):2002;10-14.
3. Rafii S., et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer. 2:2002;826-835.
4. Karkkainen M.J., et al. Lymphatic endothelium: a new frontier of metastasis research. Nat. Cell Biol. 4:2002;E2-E5.
5. Carmeliet P., et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 5:1999;495-502.
6. Senger D.R., et al. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 46:1986;5629-5632.
7. Forsythe J.A., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16:1996;4604-4613.
8. Nagy J.A., et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med. 196:2002;1497-1506.
9. Jussila L., Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol. Rev. 82:2002;673-700.
10. Lyttle D.J., et al. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J. Virol. 68:1994;84-92.
11. Fong G.H., et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 376:1995;66-70.
12. Fong G.H., et al. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development. 126:1999;3015-3025.
13. Clark D.E., et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol. Reprod. 59:1998;1540-1548.
14. Hiratsuka S., et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. U. S. A. 95:1998;9349-9354.
15. Gerber H.P., et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 417:2002;954-958.
16. Hattori K., et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med. 8:2002;841-849.
17. Sawano A., et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood. 97:2001;785-791.
18. Barleon B., et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 87:1996;3336-3343.
19. Clauss M., et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem. 271:1996;17629-17634.
20. Hiratsuka S., et al. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 61:2001;1207-1213.
21. Lyden D., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7:2001;1194-1201.
22. Luttun A., et al. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann. N. Y. Acad. Sci. 979:2002;80-93.
23. Korpelainen E.I., et al. Overexpression of VEGF in testis and epididymis causes infertility in transgenic mice: evidence for nonendothelial targets for VEGF. J. Cell Biol. 143:1998;1705-1712.
24. Niida S., et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J. Exp. Med. 190:1999;293-298.
25. Sawano A., et al. The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCγ Biochem. Biophys. Res. Commun. 238:1997;487-491.
26. Ito N., et al. Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules. J. Biol. Chem. 273:1998;23410-23418.
27. Zeng H., et al. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J. Biol. Chem. 276:2001;26969-26979.
28. Rahimi N., et al. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J. Biol. Chem. 275:2000;16986-16992.
29. Huang K., et al. Signaling properties of VEGF receptor-1 and -2 homo- and heterodimers. Int. J. Biochem. Cell Biol. 33:2001;315-324.
30. Katoh O., et al. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 55:1995;5687-5692.
31. Shalaby F., et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 376:1995;62-66.
32. Waltenberger J., et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269:1994;26988-26995.
33. Wu L.W., et al. VRAP is an adaptor protein that binds KDR, a receptor for vascular endothelial cell growth factor. J. Biol. Chem. 275:2000;6059-6062.
34. Warner A.J., et al. The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells. Biochem. J. 347:2000;501-509.
35. Takahashi T., et al. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells. EMBO J. 20:2001;2768-2778.
36. Takahashi T., et al. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 18:1999;2221-2230.
37. Meadows K.N., et al. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J. Biol. Chem. 276:2001;49289-49298.
38. Shu X., et al. Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases. Mol. Cell. Biol. 22:2002;7758-7768.
39. Gerber H.P., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273:1998;30336-30343.
40. Fulton D., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 399:1999;597-601.
41. Dimmeler S., et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 399:1999;601-605.
42. Eriksson A., et al. Small GTP-binding protein Rac is an essential mediator of vascular endothelial growth factor-induced endothelial fenestrations and vascular permeability. Circulation. 107:2003;1532-1538.
43. Rousseau S., et al. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene. 15:1997;2169-2177.
44. Qi J.H., Claesson-Welsh L. VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. Exp. Cell Res. 263:2001;173-182.
45. Eliceiri B.P., et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell. 4:1999;915-924.
46. Gitay-Goren H., et al. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem. 267:1992;6093-6098.
47. Soker S., et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 92:1998;735-745.
48. Neufeld G., et al. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc. Med. 12:2002;13-19.
49. Kawasaki T., et al. A requirement for neuropilin-1 in embryonic vessel formation. Development. 126:1999;4895-4902.
50. Yuan L., et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development. 129:2002;4797-4806.
51. Carmeliet P., et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell. 98:1999;147-157.
52. Esser S., et al. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J. Cell Sci. 111:1998;1853-1865.
53. Behzadian M.A., et al. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J. 17:2003;752-754.
54. Henderson B.R., Fagotto F. The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep. 3:2002;834-839.
55. Pajusola K., et al. Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene. 9:1994;3545-3555.
56. Pajusola K., et al. Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. Oncogene. 8:1993;2931-2937.
57. Galland F., et al. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene. 8:1993;1233-1240.
58. Baust C., et al. HERV-K-T47D-related long terminal repeats mediate polyadenylation of cellular transcripts. Genomics. 66:2000;98-103.
59. Dumont D.J., et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science. 282:1998;946-949.
60. Hamada K., et al. VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. Blood. 96:2000;3793-3800.
61. Makinen T., et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 20:2001;4762-4773.
62. Karkkainen M.J., Alitalo K. Lymphatic endothelial regulation, lymphoedema, and lymph node metastasis. Semin. Cell Dev. Biol. 13:2002;9-18.
63. Makinen T., et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 7:2001;199-205.
64. He Y., et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst. 94:2002;819-825.
65. Stacker S.A., et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7:2001;186-191.
66. Skobe M., et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7:2001;192-198.
67. Padera T.P., et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 296:2002;1883-1886.
68. Witmer A.N., et al. Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J. Histochem. Cytochem. 50:2002;767-777.
69. Witmer A.N., et al. VEGFR-3 in adult angiogenesis. J. Pathol. 195:2001;490-497.
70. Matsumura K., et al. Modulation of VEGFR-2-mediated endothelial-cell activity by VEGF-C/VEGFR-3. Blood. 101:2003;1367-1374.
71. Dixelius J., et al. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J. Biol. Chem. 2003;. doi 10.1074/jbc.M304499200.
72. Lu M., Adamis A.P. Vascular endothelial growth factor gene regulation and action in diabetic retinopathy. Ophthalmol. Clin. North Am. 15:2002;69-79.
73. LeCouter J., et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science. 299:2003;890-893.
74. Maynard S.E., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111:2003;649-658.
75. Alitalo K., Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 1:2002;219-227.
76. Saaristo A., et al. Insights into the molecular pathogenesis and targeted treatment of lymphedema. Ann. N. Y. Acad. Sci. 979:2002;94-110.
77. Roberts W.G., Palade G.E. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res. 57:1997;765-772.
78. Feng D., et al. Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation. 6:1999;23-44.
79. Bergers G., et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284:1999;808-812.
80. Bergers G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2:2000;737-744.